Prostate Mechanical Imaging: A New Method for Prostate Assessment

Urology

Volumn 71, Issue 3, 2008, Pages 425-429

  Weiss, Robert E ^a   Egorov, Vladimir ^b   Ayrapetyan, Suren ^b   Sarvazyan, Noune ^b   Sarvazyan, Armen ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ARTANN Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; ROC CURVE; STUDENT T TEST; TRANSRECTAL ULTRASONOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DIAGNOSTIC TECHNIQUES, UROLOGICAL; EQUIPMENT DESIGN; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATE; STRESS, MECHANICAL;

EID: 40649112894     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.021     Document Type: Article

References (30)

1. Stephenson R.A. Prostate cancer trends in the era of prostate-specific antigen: an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 29 (2002) 173-181
2. Ilic D., O'Connor D., Green S., et al. Screening for prostate cancer. Cochrane Database Syst Rev 3 (2006) CD004720
3. Gohagan J.K., Prorok P.C., Hayes R.B., et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21 (2000) 251S-272S
4. Schroder F.H. The European Screening Study for Prostate Cancer. Can J Oncol 4 Suppl 1 (1994) 102-105 discussion 106-109
5. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
6. Etzioni R., Penson D.F., Legler J.M., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Ins 94 (2002) 981-990
7. Tornblom M., Eriksson H., Franzen S., et al. Lead time associated with screening for prostate cancer. Int J Cancer 108 (2004) 122-129
8. Mistry K., and Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 16 (2003) 95-101
9. Partin A.W., Carter H.B., Chan D.W., et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143 (1990) 747-752
10. Lange P.H., Ercole C.J., Lightner D.J., et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141 (1989) 873-879
11. Hudson M.A., Bahnson R.R., and Catalona W.J. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142 (1989) 1011-1017
12. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151 (1994) 1283-1290
13. Pedersen K.V., Carlsson P., Varenhorst E., et al. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 300 (1990) 1041-1044
14. Chodak G.W., Keller P., and Schoenberg H.W. Assessment of screening for prostate cancer using the digital rectal examination. J Urol 141 (1989) 1136-1138
15. Gustafsson O., Norming U., Almgard L.E., et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. J Urol 148 (1992) 1827-1831
16. Yamamoto T., Ito K., Ohi M., et al. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 ng/mL or less. Urology 58 (2001) 994-998
17. Sarvazyan A. Mechanical imaging: a new technology for medical diagnostics. Int J Med Inform 49 (1998) 195-216
18. Niemczyk P., Cummings K.B., Sarvazyan A.P., et al. Correlation of mechanical imaging and histopathology of radical prostatectomy specimens: a pilot study for detecting prostate cancer. J Urol 160 (1998) 797-801
19. Weiss R.E., Hartanto V., Perrotti M., et al. In vitro trial of the pilot prototype of the prostate mechanical imaging system. Urology 58 (2001) 1059-1063
20. Sarvazyan A.P. Computerized palpation is more sensitive than human finger. 12th International Symposium on Biomedical Measurements and Instrumentation (1998) 523-524 Dubrovnik-Croatia
21. Cochlin D.L., Ganatra R.H., and Griffiths D.F. Elastography in the detection of prostatic cancer. Clin Radiol 57 (2002) 1014-1020
22. Itoh A., Ueno E., Tohno E., et al. Breast disease: clinical application of US elastography for diagnosis. Radiology 239 (2006) 341-350
23. Gomez-Dominguez E., Mendoza J., Rubio S., et al. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment Pharmacol Ther 24 (2006) 513-518
24. Rago T., Santini F., Scutari M., et al. Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. J Clin Endocrinol Metab 92 (2007) 2917-2922
25. Krouskop T.A., Wheeler T.M., Kallel F., et al. Elastic moduli of breast and prostate tissues under compression. Ultrason Imaging 20 (1998) 260-274
26. Egorov V., Ayrapetyan S., and Sarvazyan A.P. Prostate mechanical imaging: 3-D image composition and feature calculations. IEEE Trans Med Imaging 25 (2006) 1329-1340
27. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 7 (2006) 355-362
28. Warlick C.A., Allaf M.E., and Carter H.B. Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy. Urol Oncol 24 (2006) 51-57
29. Patel M.I., DeConcini D.T., Lopez-Corona E., et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 171 (2004) 1520-1524
30. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5 (2004) 101-106